COST-EFFECTIVENESS MODELING OF LURBINECTEDIN AS A SECOND-LINE THERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)

被引：0
|
作者：
Su, W. [1 ]
Rengarajan, B. [2 ]
Profant, D. [2 ]
Mayo, K. [1 ]
Groff, M. [3 ]
Tremblay, G. [3 ]
Ganti, A. K. [4 ]
机构：
[1] Jazz Pharmaceut, Philadelphia, PA USA
[2] Jazz Pharmaceut, Palo Alto, CA USA
[3] Cytel Inc, Cambridge, MA USA
[4] VA Nebraska Iowa Hlth Care Syst, Omaha, NE USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE152
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF CEMIPLIMAB AS SECOND-LINE THERAPY FOR RECURRENT CERVICAL CANCER IN JAPAN
    Maeda, Y. T. Shibata
    Chen, W.
    Morimoto, K.
    Moriwaki, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2023, 26 (06) : S150 - S151
  • [32] Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom
    Lewis, G.
    Peake, M.
    Aultman, R.
    Gyldmark, M.
    Morlotti, L.
    Creeden, J.
    de la Orden, M.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2010, 38 (01) : 9 - 21
  • [33] THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER
    Djalalov, S.
    Graham, D. M.
    Beca, J.
    Hoch, J. S.
    Tsao, M. S.
    Leighl, N.
    VALUE IN HEALTH, 2014, 17 (07) : A642 - A642
  • [34] Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer A Real-World Cost-Effectiveness Analysis
    Cromwell, Ian
    van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2097 - 2103
  • [35] COST-EFFECTIVENESS OF LORLATINIB IN SECOND-LINE TREATMENT OF ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA
    Shi, S.
    Jiang, Y.
    VALUE IN HEALTH, 2023, 26 (12) : S201 - S201
  • [36] THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER
    Graham, Donna M.
    Djalalov, Sandjar
    Beca, Jaclyn
    Hoch, Jeffrey
    Tsao, Ming S.
    Cutz, Jc
    Leighl, Natasha
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1317 - S1318
  • [37] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [38] Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge
    Subbiah, V.
    Paz-Ares, L.
    Besse, B.
    Moreno, V.
    Zaman, K.
    Sala Gonzalez, M. A.
    Lopez-Vilarino, J. A.
    Fernandez, C. M.
    Kahatt, C.
    Siguero, M.
    Zeaiter, A.
    Lopez Lopez, R.
    Ponce Aix, S.
    Boni, V.
    Arrondeau, J.
    Delord, J-P.
    Martinez-Aguillo, M.
    De Nicola, L. Wannesson
    Anton Torres, A.
    Trigo Perez, J. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1034 - S1035
  • [39] OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA
    Zhou, J.
    Jiang, G.
    VALUE IN HEALTH, 2020, 23 : S54 - S54
  • [40] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    VALUE IN HEALTH, 2019, 22 : S165 - S166
12345